Literature DB >> 8849225

In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.

E O Mason1, L B Lamberth, S L Kaplan.   

Abstract

Two oxazolidinones and ceftriaxone, imipenem, rifampin, and vancomycin were tested against 162 penicillin-intermediate and 68 penicillin-resistant strains of pneumococci. U-100592 is two- to fourfold more active than U-100766 against penicillin-resistant pneumococci. The MICs of U-100592 at which 90% of the isolates were inhibited were 0.25 and 0.5 microgram/ml for penicillin-intermediate and -resistant strains, respectively, and 0.5 microgram/ml for ceftriaxone-susceptible, -intermediate, and -resistant strains. U-100592 MICs for 7 of 230 strains (2 from blood, 3 from middle-ear fluid, and 2 from the upper respiratory tract) were 1 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849225      PMCID: PMC163257     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Management of penicillin-resistant pneumococcal infections.

Authors:  I R Friedland; G R Istre
Journal:  Pediatr Infect Dis J       Date:  1992-06       Impact factor: 2.129

Review 2.  Management of antibiotic-resistant pneumococcal infections.

Authors:  K P Klugman
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

Review 3.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

4.  Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease.

Authors:  I R Friedland
Journal:  Pediatr Infect Dis J       Date:  1995-10       Impact factor: 2.129

5.  Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis.

Authors:  I R Friedland; S Shelton; M Paris; S Rinderknecht; S Ehrett; K Krisher; G H McCracken
Journal:  Pediatr Infect Dis J       Date:  1993-03       Impact factor: 2.129

6.  High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community.

Authors:  J S Duchin; R F Breiman; A Diamond; H B Lipman; S L Block; J A Hedrick; R Finger; J A Elliott
Journal:  Pediatr Infect Dis J       Date:  1995-09       Impact factor: 2.129

7.  Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management.

Authors:  S L Block; C J Harrison; J A Hedrick; R D Tyler; R A Smith; E Keegan; S A Chartrand
Journal:  Pediatr Infect Dis J       Date:  1995-09       Impact factor: 2.129

8.  Systemic infections due to Streptococcus pneumoniae relatively resistant to penicillin in a children's hospital: clinical management and outcome.

Authors:  T Q Tan; E O Mason; S L Kaplan
Journal:  Pediatrics       Date:  1992-12       Impact factor: 7.124

Review 9.  Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics.

Authors:  G H McCracken
Journal:  Pediatr Infect Dis J       Date:  1995-05       Impact factor: 2.129

  9 in total
  17 in total

1.  Pharmacokinetics and tissue penetration of linezolid following multiple oral doses.

Authors:  T Gee; R Ellis; G Marshall; J Andrews; J Ashby; R Wise
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Linezolid as rescue therapy for pneumococcal meningitis.

Authors:  Paula Ramírez; Jose M Sahuquillo; Concepción Cortés; Pedro Kot; Juan M Bonastre
Journal:  Intensive Care Med       Date:  2007-03-13       Impact factor: 17.440

Review 3.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Antibacterial agents that inhibit two-component signal transduction systems.

Authors:  J F Barrett; R M Goldschmidt; L E Lawrence; B Foleno; R Chen; J P Demers; S Johnson; R Kanojia; J Fernandez; J Bernstein; L Licata; A Donetz; S Huang; D J Hlasta; M J Macielag; K Ohemeng; R Frechette; M B Frosco; D H Klaubert; J M Whiteley; L Wang; J A Hoch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

5.  MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.

Authors:  T L Bowersock; S A Salmon; E S Portis; J F Prescott; D A Robison; C W Ford; J L Watts
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 6.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

7.  Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Authors:  T Schülin; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 8.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

9.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11

10.  The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria.

Authors:  S M Swaney; H Aoki; M C Ganoza; D L Shinabarger
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.